Integra LifeSciences Holdings Corporation

NASDAQ:IART

Medical - Devices

Healthcare
$13.86 +4.71%

+$0.81 today

Market cap
$1.08B
Beta
1.25
P/E (TTM)
-2.8
EPS (TTM)
-$6.44
52W Low $8.70High $18.26

Volume 0.58M

Average 0.96M

IART Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Integra LifeSciences Holdings CorporationNASDAQ: IART

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $38.43M rose 3.3% year over year, in line with the +3.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.

Context

  • Depreciation & amortization amounted to 9.3% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.3% toward the trailing-twelve-month pace of +3.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.43M+0.0% QoQ
Last fiscal yearDec 2025
$151.83M+7.8% YoY
LTMMar 2026
$153.07M+3.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+7.8%——
3-year CAGR+8.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
151.83M USD
Year-over-year change
+7.8%
4-year CAGR
+6.1%

Depreciation & Amortization vs competitors

How IART compares with its peers on the latest reported figures

  • IART's LTM Mar 2026 depreciation & amortization of $153.07M is the 4th largest of the 11 companies compared; the peer median is $74.46M.
  • Its year-over-year change of +3.8% is the 5th highest of 11, against a peer median of +3.5%.
  • Depreciation & amortization amounts to 9.3% of revenue for IART, versus a peer median of 5.0%.
IART Competitors Peer median
Depreciation & Amortization for IART and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$1.25B +13.3%+6.1%4.8%
SNNSmith & Nephew plcFY2025$573M +3.2%+1.5%9.3%
GMEDGlobus Medical, Inc.LTM Jun 2026$280.81M +3.3%+59.5%8.9%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$153.07M +3.8%+8.7%9.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$136.43M +43.1%+37.4%16.5%
ATECAlphatec Holdings, Inc.LTM Mar 2026$88.73M +3.7%+33.7%11.3%
CNMDCONMED CorporationLTM Mar 2026$60.2M -10.3%+2.2%4.4%
AORTArtivion, Inc.LTM Mar 2026$23.35M -1.6%+0.0%5.1%
AXGNAxoGen, Inc.LTM Sep 2026$8.91M +19.5%+19.1%3.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$4.68M +9.1%+59.3%3.8%
TELATELA Bio, Inc.LTM Jun 2026$1M -5.9%-5.2%1.3%
Peer median (excluding IART) $74.46M+3.5%+12.6%5.0%

Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income169.08M180.55M67.74M(6.94M)(516.47M)
Depreciation & Amortization119.84M118.3M123.51M140.89M151.83M
Deferred Income Tax(2.76M)(4.59M)(11.89M)(20.73M)(66.26M)
Stock-Based Compensation36.21M27.73M20.14M24.38M18.58M
Change in Working Capital18.16M(39.42M)(81.57M)(31.01M)(33.74M)
Accounts Receivables7.27M(33.91M)4.59M7.4M(485K)
Inventory5.37M(29.12M)(59.77M)(28.15M)(46.76M)
Accounts Payables32.87M17.34M(20.23M)(2.67M)26.72M
Other Working Capital(27.35M)6.27M(6.17M)(7.58M)(13.22M)
Other Non-Cash Items(28.1M)(18.1M)22.02M22.79M496.44M
Operating Cash Flow312.43M264.47M139.96M129.38M50.38M
Capital Expenditures(48.08M)(47.09M)(66.87M)(104.42M)(95.64M)
Acquisitions (Net)(113.44M)(27.55M)0(277.81M)0
Purchases of Investments0(4.91M)(32.69M)(49M)(19.43M)
Sales of Investments76K4.91M5.38M54.5M7M
Other Investing Activities(55K)16.05M0(14.08M)(14.2M)
Investing Cash Flow(161.44M)(58.58M)(94.18M)(390.81M)(108.06M)
Debt Repayment(100M)(107.8M)54.5M299.37M46.75M
Common Stock Issued6.82M000957K
Common Stock Repurchased0(125M)(275M)(52.47M)(221K)
Dividends Paid00000
Other Financing Activities(5.05M)(24.62M)(9.43M)(9.04M)(19.15M)
Financing Cash Flow(98.23M)(251.95M)(229.93M)237.86M28.34M
Effect of Forex Changes(9.48M)(10.72M)3.89M(6.46M)18.02M
Net Change in Cash43.28M(56.79M)(180.26M)(30.03M)(11.33M)
Free Cash Flow264.35M217.38M73.09M24.96M(45.25M)

Integra LifeSciences Holdings Corporation

NASDAQ:IART

Intrinsic Alpha fair value

Locked

Current Price

$13.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.